论文部分内容阅读
目的:探讨非小细胞肺癌(non-small-cell lung cancer,NSCLC)组织中间变性淋巴瘤激酶(anaplasticlymphoma kinase,ALK)和表皮生长因子受体(epidermal growth factor receptor,EGFR)蛋白的表达情况,并分析其临床及病理意义。方法:采用免疫组织化学Elivison法检测100例NSCLC患者的手术切除标本中ALK和EGFR蛋白的表达。结果:ALK蛋白阳性表达率为14%,在病理类型、吸烟史及肿瘤分化程度之间阳性表达率有显著性差异,而在年龄、性别、临床分期及有无淋巴结转移之间无显著性差异;EGFR蛋白在NSCLC中的阳性表达率为53%,在性别及有无淋巴结转移之间阳性表达率有显著性差异,而在年龄、病理类型、肿瘤分化程度、吸烟史及临床分期之间无显著性差异。结论:ALK和EGFR蛋白在NSCLC中有过度表达,可能与NSCLC的发生、发展过程相关。
Objective: To investigate the expression of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) protein in non-small-cell lung cancer (NSCLC) Analysis of its clinical and pathological significance. Methods: Immunohistochemical Elivison method was used to detect the expression of ALK and EGFR in 100 cases of NSCLC specimens. Results: The positive expression rate of ALK protein was 14%. There was a significant difference in the positive expression rate of ALK protein between pathological types, smoking history and tumor differentiation degree, but there was no significant difference in age, gender, clinical stage and lymph node metastasis The positive expression rate of EGFR protein in NSCLC was 53%. There was a significant difference in the positive expression rate of EGFR protein between NSCLC and gender, with or without lymph node metastasis, but no significant difference between the age, pathological type, tumor differentiation, smoking history and clinical stage Significant difference. Conclusion: The overexpression of ALK and EGFR proteins in NSCLC may be related to the occurrence and development of NSCLC.